Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viwit Pharmaceuticals' Bimatoprost Eye Drops Receive Official Approval by China NMPA
Details : Bimatoprost-Generic is the first prostaglandin analog that is preservative free for the reduction of elevated intraocular pressure in patients with open-angled glaucoma or ocular hypertension.
Product Name : Bimatoprost-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable